Lipodystrophic syndromes: congenital or acquired diseases of adipose tissue;Les syndromes lipodystrophiques : des adipopathies congénitales ou acquises

Comptes Rendus - Biologies

Volumn 329, Issue 8, 2006, Pages 639-652

  Capeau, Jacqueline ^a,b   Vigouroux, Corinne ^a,b   Magré, Jocelyne ^a   Lascols, Olivier ^a   Caron, Martine ^a   Bastard, Jean Philippe ^a,b  

^a INSERM   (France)

^b HÔPITAL TENON   (France)

Author keywords

Alterations of lipid and glucose metabolism; Genetic or acquired diseases; HIV antiretroviral treatment; Hypercorticism; Insulin resistance; Lipodystrophy; Metabolic syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIN A; LAMIN C; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

CYTOLOGY; DISEASE TREATMENT; GENETIC ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; MUTATION; SUGAR;

BODY FAT; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FAMILIAL DISEASE; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; GLUCOSE METABOLISM; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERADRENOCORTICISM; INSULIN RESISTANCE; LIPID METABOLISM; LIPOATROPHY; LIPODYSTROPHY; LIPOMATOSIS; METABOLIC SYNDROME X; MITOCHONDRIAL TOXICITY; PREMATURE AGING; PREVALENCE; PROTEIN DEGRADATION; SHORT SURVEY;

ADIPOSE TISSUE; ANIMALS; DISEASE MODELS, ANIMAL; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPODYSTROPHY; MICE;

EID: 33746111155     PISSN: 16310691     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crvi.2005.11.008     Document Type: Short Survey

References (49)

1. Garg A. Acquired and inherited lipodystrophies. N. Engl. J. Med. 18 (2004) 1220-1234
2. Rodriguez A.M., Elabd C., Amri E.Z., Ailhaud G., and Dani C. The human adipose tissue is a source of multipotent stem cells. Biochimie 87 (2005) 125-128
3. Shimomura I., Hammer R.E., Richardson J.A., Ikemoto S., Bashmakov Y., Goldstein J.L., and Brown M.S. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 15 (1998) 3182-3194
4. Kim J.K., Gavrilova O., Chen Y., Reitman M.L., and Shulman G.I. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J. Biol. Chem. 275 (2000) 8456-8460
5. Gavrilova O., Marcus-Samuels B., Graham D., Kim J.K., Shulman G.I., Castle A.L., Vinson C., Eckhaus M., and Reitman M.L. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105 (2000) 271-278
6. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8 (2002) 1288-1295
7. Magre J., Delepine M., Khallouf E., Gedde-Dahl Jr. T., Van Maldergem L., Sobel E., Papp J., Meier M., Megarbane A., Bachy A., Verloes A., d'Abronzo F.H., Seemanova E., Assan R., Baudic N., Bourut C., Czernichow P., Huet F., Grigorescu F., de Kerdanet M., Lacombe D., Labrune P., Lanza M., Loret H., Matsuda F., Navarro J., Nivelon-Chevalier A., Polak M., Robert J.-J., Tric P., Tubiana-Rufi N., Vigouroux C., Weissenbach J., Savasta S., Maassen J.A., Trygstad O., Bogalho P., Freitas P., Medina J.L., Bonnicci F., Joffe B.I., Loyson G., Panz V.R., Raal F.J., O'Rahilly S., Stephenson T., Kahn C.R., Lathrop M., Capeau J., and BSCL Working Group. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat. Genet. 28 (2001) 365-370
8. Windpassinger C., Auer-Grumbach M., Irobi J., Patel H., Petek E., Horl G., Malli R., Reed J.A., Dierick I., Verpoorten N., Warner T.T., Proukakis C., Van den Bergh P., Verellen C., Van Maldergem L., Merlini L., De Jonghe P., Timmerman V., Crosby A.H., and Wagner K. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat. Genet. 36 (2004) 271-276
9. Agarwal A.K., Arioglu E., De Almeida S., Akkoc N., Taylor S.I., Bowcock A.M., Barnes R.I., and Garg A. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat. Genet. 31 (2002) 21-23
10. Magre J., Delepine M., Van Maldergem L., Robert J.-J., Maassen J.A., Meier M., Panz V.R., Kim C.A., Tubiana-Rufi N., Czernichow P., Seemanova E., Buchanan C.R., Lacombe D., Vigouroux C., Lascols O., Kahn C.R., Capeau J., and Lathrop M. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes 52 (2003) 1573-1578
11. Andreelli F., Hanaire-Broutin H., Laville M., Tauber J.-P., Riou J.-P., and Thivolet C. Normal reproductive function in leptin-deficient patients with lipoatropic diabetes. J. Clin. Endocrinol. Metab. 85 (2000) 715-719
12. Oral E.A., Simha V., Ruiz E., Andewelt A., Premkumar A., Snell P., Wagner A.J., DePaoli A.M., Reitman M.L., Taylor S.I., Gorden P., and Garg A. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346 (2002) 570-578
13. George S., Rochford J.J., Wolfrum C., Gray S.L., Schinner S., Wilson J.C., Soos M.A., Murgatroyd P.R., Williams R.M., Acerini C.L., Dunger D.B., Barford D., Umpleby A.M., Wareham N.J., Davies H.A., Schafer A.J., Stoffel M., O'Rahilly S., and Barroso I. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 28 (2004) 1325-1328
14. Vigouroux C., Magre J., Vantyghem M.C., Bourut C., Lascols O., Shackleton S., Lloyd D.J., Guerci B., Padova G., Valensi P., Grimaldi A., Piquemal R., Touraine P., Trembath R.C., and Capeau J. Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes 49 (2000) 1958-1962
15. Misteli T., and Scaffidi P. Genome instability in progeria: when repair gets old. Nat. Med. 11 (2005) 718-719
16. Bonne G., Di Barletta M.R., Varnous S., Becane H.M., Hammouda E.H., Merlini L., Muntoni F., Greenberg C.R., Gary F., Urtizberea J.A., Duboc D., Fardeau M., Toniolo D., and Schwartz K. Mutations in the gene encoding lamin A/C cause autosomal dominant Émery-Dreyfuss muscular dystrophy. Nat. Genet. 21 (1999) 285-288
17. Cao H., and Hegele R.A. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet. 9 (2000) 109-112
18. Shackleton S., Lloyd D.J., Jackson S.N., Evans R., Niermeijer M.F., Singh B.M., Schmidt H., Brabant G., Kumar S., Durrington P.N., Gregory S., O'Rahilly S., and Trembath R.C. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat. Genet. 24 (2000) 153-156
19. Vigouroux C. Laminopathies: lipodystrophies, insulin resistance, syndromes of accelerated ageing... and others. Ann. Endocrinol. 66 (2005) 270-278
20. Caux F., Dubosclard E., Lascols O., Buendia B., Chazouilleres O., Cohen A., Courvalin J.-C., Laroche L., Capeau J., Vigouroux C., and Christin-Maître S. A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. J. Clin. Endocrinol. Metab. 88 (2003) 1006-1013
21. Young J., Morbois-Trabut L., Couzinet B., Lascols O., Dion E., Bereziat V., Feve B., Richard I., Capeau J., Chanson P., and Vigouroux C. Type-A insulin resistance syndrome revealing a novel lamin A mutation. Diabetes 54 (2005) 1873-1878
22. Vigouroux C., Auclair M., Dubosclard E., Pouchelet M., Capeau J., Courvalin J.C., and Buendia B. Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q/W mutations in the lamin A/C gene. J. Cell Sci. 114 (2001) 4459-4468
23. Lammerding J., Schulze P.C., Takahashi T., Kozlov S., Sullivan T., Kamm R.D., Stewart C.L., and Lee R.T. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J. Clin. Invest. 113 3 (2004) 370-378
24. Lloyd D.J., Trembath R.C., and Shackleton S. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum. Mol. Genet. 11 (2002) 769-777
25. De Sandre-Giovannoli A., Bernard R., Cau P., Navarro C., Amiel J., Boccaccio I., Lyonnet S., Stewart C.L., Munnich A., Le Merrer M., and Levy N. Lamin-A truncation in Hutchinson-Gilford progeria. Science 300 (2003) 2055
26. Fong L.G., Ng J.K., Meta M., Cote N., Yang S.H., Stewart C.L., Sullivan T., Burghardt A., Majumdar S., Reue K., Bergo M.O., and Young S.G. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc. Natl Acad. Sci. USA 101 (2004) 18111-18116
27. Liu B., Wang J., Chan K.M., Tjia W.M., Deng W., Guan X., Huang J.D., Li K.M., Chau P.Y., Chen D.J., Pei D., Pendas A.M., Cadinanos J., Lopez-Otin C., Tse H.F., Hutchison C., Chen J., Cao Y., Cheah K.S., Tryggvason K., and Zhou Z. Genomic instability in laminopathy-based premature aging. Nat. Med. 11 (2005) 780-785
28. Varela I., Cadinanos J., Pendas A.M., Gutierrez-Fernandez A., Folgueras A.R., Sanchez L.M., Zhou Z., Rodriguez F.J., Stewart C.L., Vega J.A., Tryggvason K., Freije J.M., and Lopez-Otin C. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 437 (2005) 564-568
29. Barroso I., Gurnell M., Crowley V.E., Agostini M., Schwabe J.W., Soos M.A., Maslen G.L., Williams T.D., Lewis H., Schafer A.J., Chatterjee V.K., and O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 (1999) 880-883
30. Alberti K.G., Zimmet P., Shaw J., and IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - A new worldwide definition. Lancet 366 (2005) 1059-1062
31. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S., and RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
32. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352 (2005) 48-62
33. Jain R.G., Furfine E.S., Pedneault L., White A.J., and Lenhard J.M. Metabolic complications associated with antiretroviral therapy. Antiviral Res. 51 (2001) 151-177
34. Gougeon M.L., Penicaud L., Fromenty B., Leclercq P., Viard J.-P., and Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir. Ther. 9 (2004) 161-177
35. Nolan D., and Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir. Ther. 9 (2004) 849-863
36. Caron M., Auclair M., Lagathu C., Lombes A., Walker U.A., Kornprobst M., and Capeau J. HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 18 (2004) 2127-2136
37. Lagathu C., Bastard J.-P., Auclair M., Maachi M., Kornprobst M., Capeau J., and Caron M. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir. Ther. 9 (2004) 911-920
38. Dowell P., Flexner C., Kwiterovich P.O., and Lane M.D. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J. Biol. Chem. 275 (2000) 41325-41332
39. Caron M., Auclair M., Vigouroux C., Glorian M., Forest C., and Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50 (2001) 1378-1388
40. Caron M., Auclair M., Sterlingot H., Kornprobst M., and Capeau J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 17 (2003) 2437-2444
41. Hadri K.E., Glorian M., Monsempes C., Dieudonne M.N., Pecquery R., Giudicelli Y., Andreani M., Dugail I., and Feve B. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J. Biol. Chem. 279 (2004) 15130-15141
42. Martin A., Smith D.E., Carr A., Ringland C., Amin J., Émery S., Hoy J., Workman C., Doong N., Freund J., Cooper D.A., and Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18 (2004) 1029-1036
43. Domingo P., Matias-Guiu X., Pujol R.M., Francia E., Lagarda E., Sambeat M.A., and Vazquez G. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 13 (1999) 2261-2267
44. Nolan D., Hammond E., Martin A., Taylor L., Herrmann S., McKinnon E., Metcalf C., Latham B., and Mallal S. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 17 (2003) 1329-1338
45. Jan V., Cervera P., Maachi M., Baudrimont M., Kim M., Vidal H., Girard P.M., Levan P., Rozenbaum W., Lombes A., Capeau J., and Bastard J.-P. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir. Ther. 9 (2004) 555-564
46. Bastard J.-P., Caron M., Vidal H., Jan V., Auclair M., Vigouroux C., Luboinski J., Laville M., Maachi M., Girard P.M., Rozenbaum W., Levan P., and Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359 (2002) 1026-1031
47. Stulnig T.M., and Waldhausl W. 11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes. Diabetologia 47 (2004) 1-11
48. Hegele R.A. Premature atherosclerosis associated with monogenic insulin resistance. Circulation 103 (2001) 2225-2229
49. Petersen K.F., Dufour S., Befroy D., Garcia R., and Shulman G.I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 350 (2004) 664-671